Rates of Endometriosis Recurrence and Pregnancy 1 Year after Treatment with Intranasal Buserelin Acetate (Suprecur). A Prospective Study.
|
Accession number;99A0518587
|
| Title;Rates of Endometriosis Recurrence and Pregnancy 1 Year after Treatment with Intranasal Buserelin Acetate (Suprecur). A Prospective Study. |
| Author;
MORI H
(Teikyo Univ., Tokyo, Jpn)
TAKETANI Y
(Univ. Tokyo, Tokyo, Jpn)
UEMURA T
(Yokohama City Univ. School Of Medicine, Yokohama, Jpn)
MIYAKE A
(Osaka Univ. Medical School, Osaka, Jpn)
TANGO T
(Inst. Public Health, Tokyo, Jpn)
|
Journal Title;J Obstet Gynaecol Res
|
Journal Code:Y0696A
|
ISSN:1341-8076
|
|
VOL.25;NO.3;PAGE.153-164(1999)
|
| Figure&Table&Reference;FIG.8, TBL.3, REF.11 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Objectives: This multicenter prospective study of buserelin acetate (Suprecur) therapy for endometriosis was performed in order to examine pregnancy rates and the recurrence of endometriosis 1 year after the end of intranasal administration. Methods: This study was conducted at 349 institutions, including university hospitals and major hospitals in Japan, and 1,284 patients were recruited as participants. Recurrence of symptoms was followed for 1 year after the end of administration of buserelin acetate in patients whose condition as a whole was evaluated as "improved" or better at the end of administration. Furthermore, the pregnancy rate was similarly followed in patients who complained of sterility at the commencement of the administration. Recurrence was defined as either a case in which all of the main symptoms observed before administration returned to the pretreatment state. or a case in which at least one symptom deteriorated compared to the pretreatment state. Kaplan-Meier's method was used for statistical analysis. Results: Among 459 patients who could be evaluated for recurrence of symptoms, the cumulative recurrence rate was 17.8% 1 year after the end of administration. Among 156 patients who could be evaluated for pregnancy, the pregnancy rate was 23.3% 1 year after the end of administration. Conclusion: Intranasal buserelin acetate therapy exhibited not only transient clinical effects during administration or immediately after the end of administration, but also exhibited specific continuing effects after the end of administration. (author abst.) |
|
|
|
Related Articles;
|
|
|
